Browse COCH

Summary
SymbolCOCH
Namecochlin
Aliases COCH-5B2; DFNA9; coagulation factor C (Limulus polyphemus homolog); cochlin; coagulation factor C homolog, c ......
Chromosomal Location14q11.2-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix
Domain PF03815 LCCL domain
PF00092 von Willebrand factor type A domain
Function

Plays a role in the control of cell shape and motility in the trabecular meshwork.

> Gene Ontology
 
Biological Process GO:0007605 sensory perception of sound
GO:0008360 regulation of cell shape
GO:0022604 regulation of cell morphogenesis
GO:0031349 positive regulation of defense response
GO:0042742 defense response to bacterium
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0050954 sensory perception of mechanical stimulus
GO:0098542 defense response to other organism
Molecular Function GO:0005518 collagen binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolCOCH
Namecochlin
Aliases COCH-5B2; DFNA9; coagulation factor C (Limulus polyphemus homolog); cochlin; coagulation factor C homolog, c ......
Chromosomal Location14q11.2-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between COCH and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCOCH
Namecochlin
Aliases COCH-5B2; DFNA9; coagulation factor C (Limulus polyphemus homolog); cochlin; coagulation factor C homolog, c ......
Chromosomal Location14q11.2-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of COCH in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.54 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolCOCH
Namecochlin
Aliases COCH-5B2; DFNA9; coagulation factor C (Limulus polyphemus homolog); cochlin; coagulation factor C homolog, c ......
Chromosomal Location14q11.2-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of COCH in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.5310.374
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.170.859
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.8070.328
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0160.974
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.7710.586
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.9410.609
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.7280.333
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.770.466
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.9640.419
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3270.753
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.050.971
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.6380.00592
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of COCH in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCOCH
Namecochlin
Aliases COCH-5B2; DFNA9; coagulation factor C (Limulus polyphemus homolog); cochlin; coagulation factor C homolog, c ......
Chromosomal Location14q11.2-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of COCH. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCOCH
Namecochlin
Aliases COCH-5B2; DFNA9; coagulation factor C (Limulus polyphemus homolog); cochlin; coagulation factor C homolog, c ......
Chromosomal Location14q11.2-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of COCH. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by COCH.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCOCH
Namecochlin
Aliases COCH-5B2; DFNA9; coagulation factor C (Limulus polyphemus homolog); cochlin; coagulation factor C homolog, c ......
Chromosomal Location14q11.2-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of COCH. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCOCH
Namecochlin
Aliases COCH-5B2; DFNA9; coagulation factor C (Limulus polyphemus homolog); cochlin; coagulation factor C homolog, c ......
Chromosomal Location14q11.2-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of COCH expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCOCH
Namecochlin
Aliases COCH-5B2; DFNA9; coagulation factor C (Limulus polyphemus homolog); cochlin; coagulation factor C homolog, c ......
Chromosomal Location14q11.2-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between COCH and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCOCH
Namecochlin
Aliases COCH-5B2; DFNA9; coagulation factor C (Limulus polyphemus homolog); cochlin; coagulation factor C homolog, c ......
Chromosomal Location14q11.2-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting COCH collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.